Quotes Snapshot > BMRN
Biomarin Pharmaceutical Inc BMRN:NASDAQ
Last Price$74.94Cboe Real-Time Last Sale as of 9:36AM ET 10/18/21
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.95(1.25%)
Bid (Size)$74.57 (200)
Ask (Size)$75.12 (62)
Day Low / High$74.94 - 75.71
Volume941.00
Read more news Recent News
View all Commentary and Analysis
Tracking Baker Brothers Portfolio - Q2 2021 Update
12:54AM ET 10/05/2021 Seeking AlphaAscendis Pharma: A Promising Platform And A Rich Valuation
9:38AM ET 9/10/2021 Seeking AlphaBioMarin: The New Obstacle To Growth
4:40PM ET 9/09/2021 Seeking AlphaWall Street Breakfast: El Salvador Adopts Bitcoin (Podcast)
8:08AM ET 9/07/2021 Seeking AlphaCompany Profile
Business DescriptionBioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA. View company web site for more details
| Address | 770 Lindaro Street San Rafael, California 94901 |
| Phone | +1.415.506.6700 |
| Number of Employees | 2,849 |
| Chairman & Chief Executive Officer | Jean-Jacques Bienaimé |
| Chief Financial Officer & Executive Vice President | Brian R. Mueller |
| Chief Information Officer | Eduardo E. Von Pervieux |
| President-Worldwide Research & Development | Henry J. Fuchs |
Company Highlights
| Price Open | $75.71 |
| Previous Close | $75.89 |
| 52 Week Range | $71.65 - 92.57 |
| Market Capitalization | $13.7 B |
| Shares Outstanding | 183.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 10/27/2021 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | 17.69 |
| Earnings per Share | $4.28 |
| Beta vs. S&P 500 | N/A |
| Revenue | $1.5 B |
| Net Profit Margin | 43.64% |
| Return on Equity | 20.22% |
Analyst Ratings as of 09/08/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |